Keros Therapeutics (KROS) Other Gross PP&E Adjustments: 2019-2025
Historic Other Gross PP&E Adjustments for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to -$17.5 million.
- Keros Therapeutics' Other Gross PP&E Adjustments rose 11.91% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.8 million, marking a year-over-year decrease of 5.86%. This contributed to the annual value of -$19.6 million for FY2024, which is 3.21% up from last year.
- As of Q3 2025, Keros Therapeutics' Other Gross PP&E Adjustments stood at -$17.5 million, which was up 3.37% from -$18.1 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Other Gross PP&E Adjustments peaked at $1.1 million during Q4 2021, and registered a low of -$20.3 million during Q4 2023.
- Over the past 3 years, Keros Therapeutics' median Other Gross PP&E Adjustments value was -$17.5 million (recorded in 2025), while the average stood at -$16.1 million.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first spiked by 96.47% in 2021, then slumped by 3,405.37% in 2023.
- Keros Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $1.1 million in 2021, then slumped by 1,196.59% to -$12.2 million in 2022, then slumped by 65.96% to -$20.3 million in 2023, then climbed by 3.21% to -$19.6 million in 2024, then rose by 11.91% to -$17.5 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$17.5 million for Q3 2025, versus -$18.1 million for Q2 2025 and -$18.7 million for Q1 2025.